Yissum - Research Development Company of the Hebrew University

Generation of Human Induced Trophoblast Stem Cells for Modelling and Treating Placental Dysfunction Diseases

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Project ID : 6-2019-6716

Description of the technology

Categories

Stem-cell therapy, Women’s health, Fertility

Development Stage

In vivo POC

Background

  • Recurrent miscarriage,preeclampsia and intra-uterine growth restriction (IUGR) are three common implantation (placental)-related diseases and a major cause of mortality and morbidity for mother and child, complicating between 3 to 10 percent of pregnancies, with increasing rates in recent years.
  • It is estimated that dysfunctional placental stem cells (i.e. trophoblast stem cells (TSCs)) or early differentiating trophoblastic cells are a major cause leading to these diseases.
  • Regenerative medicine is a new and expanding area that aims to replace lost or damaged cells, tissues or organs in the human body through cellular transplantation.
  • The conversion of fibroblasts into other cell types by the direct conversion approach opened an attractive avenue that resolves ethical issue and the immune rejection problem and the need for donor cells.

Our Innovation

  • Placental dysfunction is associated with about 70% of all miscarriages. It is also a major cause of fetal growth restriction (FGR) that may lead to the birth of retarded children and death.
  • Our lab developed a novel paradigm to convert human skin cells into human induced trophoblast stem cells (hiTSCs).
  • When over expressing four TSC master regulators, we were able to successfully generate hiTSCs that exhibit similar morphology, transcriptome and methylome to their blastocyst-derived TSC counterparts and could grow stably in the absence of their exogenous factors for a long time.
  • Moreover, hiTSCs are fully functional and can successfully differentiated into all trophoblast subtypes in vitro and in NOD/SCID mice.
  • Since isolating human TSCs from healthy individuals hold major ethical problems and might exhibit immune-rejection problems, iTSCs are an excellent alternative source of cells that solve these limitations and holds great promise in regenerative medicine for the treatment of miscarriage and other placental dysfunction diseases.
  • Since hiTSCs can be isolated at late stages of pregnancy, in contrast to hTSCs that can be isolated only during the first trimester, these cells can be used to model placental dysfunction diseases and offer a great platform for drug discovery.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Yossi Buganim
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Stem Cells
  • Life Science & Biotechnology
  • placental

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.